|
|
Allergy Therapeutics PLC - Comparative Business Analysis Snapshot
Business Description
Allergy Therapeutics PLC. The Group's principal activity is developing, manufacturing, marketing and selling a range of pharmaceutical vaccine products designed for the immunological treatment of the allergic condition. Vaccinations take the form of allergen-specific, named-patient-specific and standard products in injectable and sublingual presentations. The Group's allergy vaccination focuses on advance of progressive allergic conditions that can often culminate in severe, life-threatening asthma. Product brands are Pollinex Quattro and Oralvac Plus. The Group's product focuses on Ultra-short-course vaccines for allergy to major pollens and sublingual vaccines for allergy to major pollens, house dust mite and cat.
Competitor Analysis
This analysis compares Allergy Therapeutics PLC with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
